Scarica l'app Stockscreener
26.83
1.94%
-0.53
Pre-mercato:
26.83
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BEAM Giù?
Forum
Previsione
Precedente Chiudi:
$27.36
Aprire:
$27.47
Volume 24 ore:
1.88M
Relative Volume:
0.81
Capitalizzazione di mercato:
$2.72B
Reddito:
$352.57M
Utile/perdita netta:
$-143.01M
Rapporto P/E:
-14.82
EPS:
-1.81
Flusso di cassa netto:
$-153.40M
1 W Prestazione:
-1.00%
1M Prestazione:
+23.53%
6M Prestazione:
+57.27%
1 anno Prestazione:
-3.94%
Intervallo 1D:
$26.56
$28.10
Intervallo di 1 settimana:
$25.86
$28.28
Portata 52W:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Nome
Beam Therapeutics Inc
Settore
Industria
Telefono
857-327-8775
Indirizzo
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Confronta BEAM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
26.83 | 2.78B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Iniziato | Jefferies | Buy |
| 2025-03-28 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-10 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-29 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-08 | Downgrade | Jefferies | Buy → Hold |
| 2023-10-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | Iniziato | Citigroup | Buy |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2022-01-05 | Iniziato | Guggenheim | Buy |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-09-24 | Ripresa | Stifel | Buy |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-05-11 | Iniziato | Redburn | Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-16 | Iniziato | Wells Fargo | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-08-05 | Iniziato | William Blair | Outperform |
| 2020-03-02 | Iniziato | Barclays | Overweight |
| 2020-03-02 | Iniziato | JP Morgan | Overweight |
| 2020-03-02 | Iniziato | Jefferies | Buy |
| 2020-03-02 | Iniziato | Wedbush | Outperform |
Mostra tutto
Beam Therapeutics Inc Borsa (BEAM) Ultime notizie
Nikko Asset Management Americas Inc. Increases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Bellevue Group AG Raises Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
Beam Therapeutics Inc. $BEAM Holdings Lowered by Redmile Group LLC - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Evercore ISI Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
Beam Therapeutics (BEAM) Receives a Buy from Bank of America Securities - The Globe and Mail
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
Beam Therapeutics stock rises on promising sickle cell therapy data By Investing.com - Investing.com Nigeria
Beam Therapeutics stock rises on promising sickle cell therapy data - Investing.com
(BEAM) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Reveals Positive Trial Results at Hemat - GuruFocus
Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON Sickle Cell Trial Results and Renewed Momentum - Yahoo Finance
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential - Yahoo Finance
Beam reports positive data from sickle cell disease gene therapy trial By Investing.com - Investing.com South Africa
Beam reports positive data from sickle cell disease gene therapy trial - Investing.com
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Reports Promising Updates on Risto-cel for Sickle Cell Disease at 67th ASH Annual Meeting - Quiver Quantitative
38,438 Shares in Beam Therapeutics Inc. $BEAM Purchased by Capital Fund Management S.A. - MarketBeat
Beam Therapeutics stock surges 64% since InvestingPro’s April undervalued call By Investing.com - Investing.com Australia
BEAM (Beam Therapeutics) Capex-to-Operating-Income : 0.00 (As of Sep. 2025) - GuruFocus
How Beam Therapeutics Inc. stock compares to industry benchmarksProfit Target & AI Powered Market Entry Strategies - Newser
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 6.8%What's Next? - MarketBeat
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? - Yahoo Finance
Published on: 2025-12-04 06:37:06 - Newser
Why analysts remain bullish on Beam Therapeutics Inc. stockJuly 2025 Trends & Community Verified Trade Signals - Newser
Beam Therapeutics (BEAM) Experiences Significant Stock Surge - GuruFocus
Will Beam Therapeutics Inc. stock split again soonSell Signal & Daily Volume Surge Trade Alerts - Newser
Will Beam Therapeutics Inc. stock pay special dividends2025 Stock Rankings & Precise Swing Trade Entry Alerts - Newser
Is Beam Therapeutics Inc. stock attractive for ETFsRate Cut & Safe Entry Point Identification - Newser
The Best CRISPR Companies for 2025 - The Motley Fool
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - MSN
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
Geode Capital Management LLC Grows Position in Beam Therapeutics Inc. $BEAM - MarketBeat
14,601 Shares in Beam Therapeutics Inc. $BEAM Bought by Entropy Technologies LP - MarketBeat
Beam Therapeutics (BEAM) Earnings Transcript - Nasdaq
How resilient is Beam Therapeutics Inc. stock in market downturnsOil Prices & Stepwise Swing Trade Plans - BỘ NỘI VỤ
Is Beam Therapeutics Inc. stock a defensive play in 20252025 Winners & Losers & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ
(BEAM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
ETFs Investing in Beam Therapeutics Inc. Stocks - TradingView
Evercore ISI Group Initiates Coverage of Beam Therapeutics (BEAM) with Outperform Recommendation - MSN
Beam Therapeutics Hits 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Beam Therapeutics (BEAM) Receives New 'Outperform' Rating from E - GuruFocus
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
How Beam Therapeutics Inc. stock valuations compare to rivals - newser.com
Beam Therapeutics Inc Azioni (BEAM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):